Parmantier & Cie. GmbH
PARMANTIER & CIE. is starting coverage of CLINUVEL Pharmaceuticals Ltd.

Frankfurt am Main, September 09, 2024 – PARMANTIER & CIE. has initiated coverage of CLINUVEL Pharmaceuticals Ltd., Melbourne. CLINUVEL Pharmaceuticals Ltd. is a biopharmaceutical company founded in 1987 and headquartered in Melbourne, Australia. The company is a leader in the development and commercialization of melanocortin-based therapies for the treatment of skin pigmentation disorders and the prevention of skin cancer. CLINUVEL is particularly well known for its flagship product SCENESSE®, an implanted drug for the treatment of the rare disease erythropoietic protoporphyria (EPP). In addition to the pharmaceutical division, CLINUVEL has also developed the nutraceuticals division to offer nutritional supplements to improve skin health.

CLINUVEL is positioned in two core sectors: pharmaceuticals and photocosmetics.

You can find our complete research report on CLINUVEL Pharmaceuticals Ltd. here:

Bloomberg/parmantiercie; Shortcode: {DS FMG <GO>}

https://www.parmantiercie.com/

Analyst Coverage – CLINUVEL

About PARMANTIER & CIE. Ltd:

PARMANTIER & CIE. specializes in advising and arranging corporate financing, be it equity, debt or hybrid forms of financing, pursuing the business approach of a traditional merchant bank. PARMANTIER & CIE. also invests in listed and unlisted companies. The company’s guiding principles are the traditional values of an honorable businessman and the development of innovative financing solutions for a changing world. The company takes risks itself and always invests its own capital. The company is characterized by a forward-looking mindset as well as the design of tailor-made, modern corporate financing for listed and unlisted companies.

Contact

Melba Victoria Grün

gruen@parmantiercie.com